Since AM80 shows enhanced potency compared to ATRA and is free from the side effects associated with RAR-γ activation [78,79], AM80 intervention may offer superior outcomes for establishing host-directed TB therapies in susceptible models compared to ATRA. The gene discussed is RARG; the disease is tuberculosis.